Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor(GIST) Clinical Trial

Official title: Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor

Status Completed

Clinical Trial Summary

To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may affect imatinib compliance. Our previous retrospective study suggested that severe skin rash induced by imatinib can be managed by systemic steroid without imatinib dose interruption or reduction. This phase II study was conducted to evaluate the efficacy and safety of systemic steroid in GIST patients with imatinib-associated severe skin rash.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Exanthema
• Gastrointestinal Stromal Tumor(GIST)
• Gastrointestinal Stromal Tumors

• NCT number: NCT03440515
• Study type: Interventional
• Source: Asan Medical Center
• Status: Completed
• Phase: Phase 2
• Start date: August 2014
• Completion date: June 2017